Ciba turns down Biosignal compounds
Wednesday, 06 August, 2008
Global specialty chemical company Ciba Corporation has decided to stop testing Biosignal's [ASX: BOS] anti-microbial industrial compounds, citing major issues incorporating the product into theirs.
Ciba was evaluating whether it could incorporate the compounds into its PVC plastic and coatings, but found that doing so resulted in high temperatures during the processing stage and incompatibility with other components.
Representatives for Biosignal said the decision did not alter expectations for the viability of the compounds, stating that it still had evaluation agreements in place with a number of companies.
These include oil producer ConocoPhillips, sanitation product manufacturers Saraya Co, and leading agrichemicals and animal health companies.
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
